Search

Retinopathy of prematurity treatment in the South West of England: long-term outcomes 1997-2008

Retinopathy of prematurity (ROP) is a condition that affects the developing retinal vascular system of pre-term babies. If left untreated, ROP can lead to severe visual impairment. The severe visual impairment caused by untreated ROP can be prevented by screening...

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...

Advances and developments in medical retina

The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Progress in retinal disease management: Highlights of the Retina Day, RCOphth 2025 Annual Congress

The Retina Day meeting at the Royal College of Ophthalmologists (RCOphth) 2025 Annual Congress in Liverpool was held on 22 May 2025. This report highlights 10 selected topics of interest to subspecialists and general ophthalmologists. Decarbonising anti-VEGF clinics (or making...